Pharmaceutical Executive January 8, 2026
Trialynx founder and CEO Angela Schwab continues her conversation with PharmExec and explains the effective ways that AI is being used to tackle common problems with clinical trial design.
Pharmaceutical Executive: How can AI life sciences companies stand out at the upcoming JP Morgan Healthcare Conference?
Angela Schwab: There’s a few different ways. In 2025, we saw a lot of AI hype, with claims of using AI for everything and it solving all our problems. The disillusionment has set in, however, and to get out of AI what we really want, you must have a massive amount of prompting and back-and-forth conversations. With that, it still hallucinates.
The companies that are standing out are the ones with the deep, domain knowledge...
Today's Sponsors
Today's Sponsor